Recent advances in the molecular pathology of soft tissue sarcoma: implications for diagnosis, patient prognosis, and...

Area of Science:

• Oncology
• Molecular Pathology
• Genetics

Background:

• Soft tissue sarcomas (STS) represent a heterogeneous group of tumors with diverse molecular underpinnings.
• Understanding the molecular pathology of STS is crucial for developing targeted therapies and improving prognostic accuracy.
• Recent advances have led to the classification of STS based on specific genetic alterations, primarily chromosome translocations.

Purpose of the Study:

• To review recent advances in the molecular pathology of soft tissue sarcomas (STS).
• To discuss the prognostic implications of these molecular findings.
• To identify potential molecular targets for therapeutic intervention in STS.

Main Methods:

• Review of recent literature on molecular pathology of STS.
• Classification of STS based on genetic features: chromosome translocation-associated versus non-translocation-associated.
• Assessment of specific molecular alterations, including fusion transcripts, tumor-suppressor genes, adhesion molecules, and growth factors.

Main Results:

• Specific fusion transcripts (e.g., SS18–SSX, EWS–FLI1) are characteristic of certain STS subtypes and interact with cell cycle regulators, marking them as potential therapeutic targets.
• Alterations in tumor-suppressor genes (e.g., SMARCB1/INI1) and overexpression of growth factors (e.g., epidermal growth factor receptor) are observed in STS, with prognostic significance.
• Epidermal growth factor receptor overexpression in mixed-type STS correlates with decreased survival, suggesting potential benefit from receptor inhibitors.
• SMARCB1/INI1 alterations are frequent in malignant rhabdoid tumor and epithelioid sarcoma, indicating its potential as a therapeutic target.
• Dysadherin overexpression in sarcomas with epithelioid differentiation is associated with poor prognosis.

Conclusions:

• Fusion transcripts in translocation-associated STS are promising molecular targets.
• Specific molecular alterations like SMARCB1/INI1 loss and EGFR overexpression offer therapeutic avenues for certain STS subtypes.
• Further research is needed to identify effective and specific molecular targets for all STS types, particularly those lacking specific translocations.